Xcout Intel
Xintela AB competitors & alternatives
The 12 closest competitors and alternatives to Xintela AB among biotech companies — ranked by similarity to what Xintela AB actually does, not by market-cap band.
Subscribe to see Xintela AB’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Xintela AB
Xintela AB is a Swedish biotechnology company developing cell therapies and regenerative-medicine products based on its integrin α10 technology. Its lead program, XSTEM, uses integrin α10-selected mesenchymal stem cells for conditions such as osteoarthritis and cartilage damage, serving patients and healthcare providers through potential advanced therapies.
Top 12 Xintela AB competitors
Ranked by semantic similarity — how close each company is to Xintela AB by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Tavra Biosciences supplies cGMP-manufactured stem cell biologics, specifically bone marrow-derived mesenchymal stem cells, to licensed physicians for localized clinical use in orthopedic and regenerative medicine. The company's off-the-shelf products are manufactured in a compliant cleanroom facility and provided to support clinical practices in sports medicine and pain management.
Biotechnology
Amplicore Inc. develops injectable therapeutics aimed at treating degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. The company focuses on regenerative and minimally invasive approaches to address the underlying causes of joint discomfort and restore mobility for patients.
Similar biotech company
CO.DON is a biopharmaceutical company specializing in tissue engineering and the development and manufacturing of personalized cell therapies. The company provides regenerative treatments for joint cartilage defects to medical professionals and patients.
Biotechnology
Cynata Therapeutics is a biotechnology research company headquartered in Cremorne, Australia, focused on therapeutic products and stem cell technology.
Similar biotech company
UnicoCell Biomed Co., Ltd., a Taiwanese enterprise, specializes in the research, development, and application of stem cell-based pharmaceuticals, advanced cell therapy techniques, and regenerative medical solutions. Their flagship product, ELIXCYTE, is presently undergoing Phase 2 clinical trials, targeting both osteoarthritis and chronic kidney disease. Beyond therapeutics, the company also offers UnicoVial, a specialized cryopreservation and drug containment system designed for cell therapy products, and provides a range of related testing services.
Biotechnology
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
Similar biotech company
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Biotechnology
Kadimastem Ltd. is a clinical-stage cell therapy company headquartered in Ness Ziona, Israel, focused on developing advanced cell-based therapeutic treatments.
Biotechnology
Novadip Biosciences is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Belgium, focusing on innovative tissue regeneration and biopharmaceuticals.
Similar biotech company
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases.
Biotechnology
BLOOCELL is a biotechnology company specializing in artificial tissue technology, focusing on advanced bone and cartilage repair matrix solutions.
Similar biotech company
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome. The company operates under a licensing agreement with Yeda Research and Development Company Limited, granting it rights for the research, development, and commercialization of hCDR1 across numerous therapeutic applications. Originally incorporated in 1993 as Xenograft Technologies Ltd., the entity rebranded as XTL Biopharmaceuticals Ltd. in July 1995 and is currently headquartered in Ramat Gan, Israel.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Xintela AB and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Xintela ABand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →